Tokyo-based Daiichi Sankyo Co. opened a clinical trial for ... Other Japanese drugmakers are trying to develop their own COVID-19 vaccines, again with no prospects in sight for their practical ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

Other Trump executive orders included repealing a 2022 Biden executive order to test Medicaid models to lower the price of drugs and orders related to access to Covid-19 vaccines and treatments.

according to a statement from drugmakers AstraZeneca and Daiichi Sankyo. (Bankhead, 1/28) Bloomberg: Merck’s $8 Billion Cancer Vaccine Faces First US Jury Trial Merck & Co. is facing its first jury ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Shionogi landed $375 million from the Department of Health and Human Services to develop a preventative drug for COVID-19. Daiichi Sankyo is spending $132.5 ... 2025 sales forecast by $1 billion on ...

Fields is now on a drug approved by the Food and Drug Administration named Enhertu, developed and commercialized by biotech giants AstraZeneca and Daiichi Sankyo. Enhertu is not specifically ...

Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against ... 2024 AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by ...

The COVID-19 pandemic further accelerated innovation ... AstraZeneca - AstraZeneca formed a partnership with Daiichi Sankyo to co-develop cancer therapies. The company also launched a biologic for ...